Healthcare Business

8 BioPharma Movers That Cannot Be Ignored

Over the past week, a few biotech companies made absolutely massive runs. In the past year, the health care sector was on fire from positive trials, U.S. Food and Drug Administration (FDA) approvals and mergers and acquisitions. These stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the course of the past week.

We have included information about each company, as well as recent trading activity and the consensus price target.

AbbVie Inc. (NYSE: ABBV) received a warning from the FDA regarding its Viekira Pak and Technivie hepatitis C treatments. It was found that these can cause serious liver injury in patients with underlying advanced liver disease. Over the course of the week, shares fell 14%, and shares are down 23.8% year to date. Shares of AbbVie traded at $50.34 on Friday’s close. The stock has a consensus analyst price target of $74.57 and a 52-week trading range of $45.45 to $71.60.

Gilead Sciences Inc. (NASDAQ: GILD) is banking off the AbbVie loss as it produces and sells the other hepatitis C treatments on the market. Over the course of the week, shares rose 5.9%, and they are up 15% year to date. The stock was at $107.99 on Friday’s close. The consensus analyst price target is $124.25, and the 52-week trading range is $84.95 to $123.37.

Endo International PLC (NASDAQ: ENDP) provided an update on its use of specialty pharmacies on Wednesday, and a majority of its drugs are not distributed using these specialty pharmacies. The broad markets did not receive this well. Over the course of the week, shares fell 22.7%, and they are down nearly 28.7% year to date. The share price ended the week at $56.60. The stock has a consensus price target of $93.47 and a 52-week range of $46.66 to $96.58.

ALSO READ: The Strongest Performing Biotech in 2015 Is a Surprise

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) saw its shares take a dive after it announced that it was giving up on a late-stage clinical trial for its lead lung cancer candidate, ganetespib. Over the course of the week, shares fell 67%. Year to date, they are down nearly 75%. Shares of Synta were at $0.67 on Friday’s close. The consensus price target is $6.00, and the 52-week trading range is $0.55 to $3.44.